Yun-Fan Liaw
Liao, Yunfan
廖運範, (醫學), 1942-
Liaw, Yun-fan
Liao, Yün-fan
VIAF ID: 62995555 (Personal)
Permalink: http://viaf.org/viaf/62995555
Preferred Forms
-
- 100 1 _ ‡a Liao, Yunfan
- 100 1 _ ‡a Liao, Yunfan
-
- 100 1 _ ‡a Liao, Yün-fan
-
- 100 1 _ ‡a Liaw, Yun-fan
- 100 0 _ ‡a Yun-Fan Liaw
-
4xx's: Alternate Name Forms (16)
Works
Title | Sources |
---|---|
Intern. Symp. on Chronic Hepatitis (1985 : Taipei, Taiwan). Chronic hepatitis, 1986: | |
Metabolic risk factors are associated with non-hepatitis B non-hepatitis C hepatocellular carcinoma in Taiwan, an endemic area of chronic hepatitis B. | |
Modulation of tumor necrosis factor receptors 1 and 2 in chronic hepatitis B and C: the differences and implications in pathogenesis. | |
Molecular cloning of a defective hepatitis C virus genome from the ascitic fluid of a patient with hepatocellular carcinoma | |
Natural course of patients with chronic type B hepatitis following acute hepatitis delta virus superinfection. | |
The natural history of chronic HBV infection and geographical differences | |
No association between IFNL3 | |
No benefit to continue lamivudine therapy after emergence of YMDD mutations | |
Nucleos(t)ide analogues for hepatitis B virus: strategies for long-term success | |
Overt acute hepatitis B is more severe in female patients. | |
Pathological rupture of spleen in hepatitis B virus-related cirrhosis | |
Pharmacotherapeutic options for hepatitis B. | |
Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion | |
Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. | |
The prevalence and incidence of cholecystolithiasis in patients with chronic liver diseases: a prospective study. | |
The prevalence of hepatitis C virus antibodies in patients treated with continuous ambulatory peritoneal dialysis | |
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection | |
Prognosis of immune-tolerant phase chronic hepatitis B. | |
Progression of the proportion of hepatitis B virus precore stop mutant following acute superinfection of hepatitis C. | |
Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors | |
Purification and characterization of a naturally processed hepatitis B virus peptide recognized by CD8+ cytotoxic T lymphocytes | |
Quantitative assessment of hepatitis C virus RNA by polymerase chain reaction and a digoxigenin detection system: comparison with branched DNA assay | |
Re-treatment for severe hepatitis flare in HBeAg-negative chronic hepatitis B: An appraisal with combined HBsAg/ALT kinetics | |
Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. | |
Relative roles of HBsAg seroclearance and mortality in the decline of HBsAg prevalence with increasing age. | |
Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up | |
Replication of hepatitis C virus in ascitic mononuclear cells with development of distinct viral quasispecies | |
Reply to "letter to the editor"-combination therapy for chronic hepatitis B: The future and beyond | |
Responding to the progress in hepatology: beyond the boundaries | |
Responses are durable for up to 5 years after completion of peginterferon alfa-2a treatment in hepatitis B e antigen-positive patients. | |
Results of lamivudine trials in Asia | |
Reversal of cirrhosis: an achievable goal of hepatitis B antiviral therapy | |
Robust antiviral responses in severe hepatitis flare persist after early retreatment cessation and lead toward hepatitis B surface antigen loss: A proof‐of‐concept study | |
Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study | |
The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. | |
Role of the ribozyme of hepatitis delta virus on the transcription after polyadenylation | |
Screening for hepatitis B virus in healthy blood donors by molecular DNA hybridization analysis | |
Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response | |
Serodiagnosis of acute B hepatitis: comparison between a competitive binding radioimmunoassay and an enzyme linked immunosorbent assay for IgM antibody to hepatitis B core antigen | |
Serum Levels of Hepatitis B Surface Antigen Predict Severity of Fibrosis in Patients With E Antigen-Positive Chronic Hepatitis B. | |
Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers | |
Shen zang ti huan zhi liao yuC xing gan yan bing du gan ran(di san nian) / Huang qiu jin, liao yun fan zhu chi, 1994 | |
Simultaneous acute hepatitis B virus and hepatitis C virus infection leading to fulminant hepatitis and subsequent chronic hepatitis C. | |
Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy. | |
Spontaneous relapse of hepatitis in inactive HBsAg carriers | |
Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients. | |
Studies on the composition of the mononuclear cell infiltrates in liver from patients with chronic active delta hepatitis | |
Sustained virological response to interferon reduces cirrhosis in chronic hepatitis C: a 1,386-patient study from Taiwan. | |
Therapy of chronic hepatitis B: current challenges and opportunities | |
Thymalfasin (thymosin-alpha 1) therapy in patients with chronic hepatitis B. | |
Thyroxine-binding globulin in patients with chronic hepatitis B virus infection: different implications in hepatitis and hepatocellular carcinoma | |
Towards a rational treatment strategy for chronic hepatitis B. | |
Treatment of chronic type B hepatitis in Southeast Asia | |
Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. | |
Vitamin A, Vitamin E or beta-carotene status and hepatitis B-related hepatocellular carcinoma. | |
White count, pH and lactate in ascites in the diagnosis of spontaneous bacterial peritonitis | |
Why most patients with hepatitis delta virus infection are seronegative for hepatitis B e antigen. A prospective controlled study | |
Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. | |
α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare | |
慢性C型肝炎之免疫學研究III = Immunological Study on Chronic C Hepatitis III : '株植分析肝內C型肝炎病毒特異性之毒殺性T淋巴球 : Cloning and Analysis of Intrahepatic Hepatitis C Virus-Specific Cytotoxic T Lymphocytes / 廖運範主持, 1996 | |
肝炎肝硬化與肝癌 / 宋瑞樓, 陳定信, 廖運範編著, 2006 | |
腎臟替換治療與C型肝炎病毒感染(第三年) / 黃秋錦, 廖運範主持, 1994 | |
陳勝崑醫師紀念集 / 廖運範等著, 1992 |